Iron dysregulation in movement disorders

Neurobiology of Disease

Volumn 46, Issue 1, 2012, Pages 1-18

  Dusek, Petr ^a,b   Jankovic, Joseph ^a   Le, Weidong ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Chelating agents; Dystonia; Iron; Neurodegeneration; Parkinson's disease

Indexed keywords

ACERULOPLASMINEMIA; AUTOSOMAL RECESSIVE DISORDER; BRAIN LEVEL; DISEASE CLASSIFICATION; FATTY ACID HYDROXYLASE ASSOCIATED NEURODEGENERATION; FRIEDREICH ATAXIA; GENETIC ASSOCIATION; HEMOCHROMATOSIS; HEREDITARY FERRITINOPATHY; HUMAN; IRON METABOLISM; KUFOR RAKEB DISEASE; MOLECULAR PATHOLOGY; MOTOR DYSFUNCTION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROPATHOLOGY; NONHUMAN; PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION; PARKINSON DISEASE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; WOODHOUSE SAKATI SYNDROME;

ANIMALS; HUMANS; IRON; IRON METABOLISM DISORDERS; MOVEMENT DISORDERS;

EID: 84858157347     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.12.054     Document Type: Review

References (278)

1. Adams P.C., Barton J.C. Haemochromatosis. Lancet 2007, 370:1855-1860.
2. Aggarwal A., et al. Indian-subcontinent NBIA: unusual phenotypes, novel PANK2 mutations, and undetermined genetic forms. Mov. Disord. 2010, 25:1424-1431.
3. Alazami A.M., et al. C2orf37 mutational spectrum in Woodhouse-Sakati syndrome patients. Clin. Genet. 2010, 78:585-590.
4. Allen R.P., Earley C.J. The role of iron in restless legs syndrome. Mov. Disord. 2007, 22(Suppl. 18):S440-S448.
5. Allen R.P., et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001, 56:263-265.
6. Al-Semari A., Bohlega S. Autosomal-recessive syndrome with alopecia, hypogonadism, progressive extra-pyramidal disorder, white matter disease, sensory neural deafness, diabetes mellitus, and low IGF1. Am. J. Med. Genet. A 2007, 143:149-160.
7. Antonini A., et al. Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration. Mov. Disord. 2006, 21:417-418.
8. Arabia G., et al. An magnetic resonance imaging T2*-weighted sequence at short echo time to detect putaminal hypointensity in Parkinsonisms. Mov. Disord. 2010, 25:2728-2734.
9. Attieh Z.K., et al. Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. J. Biol. Chem. 1999, 274:1116-1123.
10. Baraibar M.A., et al. Iron-mediated aggregation and a localized structural change characterize ferritin from a mutant light chain polypeptide that causes neurodegeneration. J. Biol. Chem. 2008, 283:31679-31689.
11. Bareggi S.R., Cornelli U. Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders. CNS Neurosci. Ther. 2010, doi:10.1111/j.1755-5949.2010.00231.x.
12. Bartels A.L., et al. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol. Aging 2009, 30:1818-1824.
13. Bartzokis G., et al. Increased basal ganglia iron levels in Huntington disease. Arch. Neurol. 1999, 56:569-574.
14. Bartzokis G., et al. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem. Res. 2007, 32:1655-1664.
15. Bartzokis G., et al. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol. Aging 2007, 28:414-423.
16. Bartzokis G., et al. Prevalent iron metabolism gene variants associated with increased brain ferritin iron in healthy older men. J. Alzheimers Dis. 2010, 20:333-341.
17. Bayot A., et al. Friedreich's ataxia: the vicious circle hypothesis revisited. BMC Med. 2011, 9:112.
18. Berg D., Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov. Disord. 2006, 21:1299-1310.
19. Berg D., et al. The basal ganglia in haemochromatosis. Neuroradiology 2000, 42:9-13.
20. Berlet H.H., Volk B. Studies of human myelin proteins during old age. Mech. Ageing Dev. 1980, 14:211-222.
21. Boddaert N., et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007, 110:401-408.
22. Borie C., et al. Association study between iron-related genes polymorphisms and Parkinson's disease. J. Neurol. 2002, 249:801-804.
23. Bras J., et al. Emerging pathways in genetic Parkinson's disease: potential role of ceramide metabolism in Lewy body disease. FEBS J. 2008, 275:5767-5773.
24. Bruggemann N., et al. Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch. Neurol. 2010, 67:1357-1363.
25. Bruggemann N., et al. Idiopathic NBIA - clinical spectrum and transcranial sonography findings. Eur. J. Neurol. 2011, 18:e58-e59.
26. Burdo J.R., et al. Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. J. Neurosci. Res. 2001, 66:1198-1207.
27. Burgetova A., et al. Multiple sclerosis and the accumulation of iron in the basal ganglia: quantitative assessment of brain iron using MRI t(2) relaxometry. Eur. Neurol. 2010, 63:136-143.
28. Caciotti A., et al. GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. Biochim. Biophys. Acta 2011, 1812:782-790.
29. Castiglioni E., et al. Sequence variations in mitochondrial ferritin: distribution in healthy controls and different types of patients. Genet. Test. Mol. Biomarkers 2010, 14:793-796.
30. Castiglioni E., et al. Analysis of nucleotide variations in genes of iron management in patients of Parkinson's disease and other movement disorders. Parkinsons Dis. 2010, 2011:827693.
31. Catoire H., et al. Restless legs syndrome-associated MEIS1 risk variant influences iron homeostasis. Ann. Neurol. 2011, 70:170-175.
32. Chan S.Y., et al. Apoptosis induced by intracellular ceramide accumulation in MDA-MB-435 breast carcinoma cells is dependent on the generation of reactive oxygen species. Exp. Mol. Pathol. 2007, 82:1-11.
33. Chang M.H., et al. Eye of the tiger-like MRI in parkinsonian variant of multiple system atrophy. J. Neural Transm. 2009, 116:861-866.
34. Chen Q., et al. High brain iron level in asymptomatic carriers of heterozygous ceruloplasmin gene mutations. Mov. Disord. 2008, 23:916-917.
35. Chew K.C., et al. Enhanced autophagy from chronic toxicity of iron and mutant A53T alpha-synuclein: implications for neuronal cell death in Parkinson disease. J. Biol. Chem. 2011, 286:33380-33389.
36. Chiapparini L., et al. The "eye-of-the-tiger" sign may be absent in the early stages of classic pantothenate kinase associated neurodegeneration. Neuropediatrics 2011, 42:159-162.
37. Chien H.F., et al. ATP13A2-related neurodegeneration (PARK9) without evidence of brain iron accumulation. Mov. Disord. 2011, 26:1364-1365.
38. Chinnery P.F., et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007, 130:110-119.
39. Cho Z.H., et al. Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging. Mov. Disord. 2011, 26:713-718.
40. Connor J.R., Menzies S.L. Altered cellular distribution of iron in the central nervous system of myelin deficient rats. Neuroscience 1990, 34:265-271.
41. Connor J.R., et al. Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J. Neurosci. Res. 1990, 27:595-611.
42. Connor J.R., et al. Is hemochromatosis a risk factor for Alzheimer's disease?. J. Alzheimers Dis. 2001, 3:471-477.
43. Connor J.R., et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003, 61:304-309.
44. Connor J.R., et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 2004, 62:1563-1567.
45. Connor J.R., et al. Profile of altered brain iron acquisition in restless legs syndrome. Brain 2011, 134:959-968.
46. Cossee M., et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann. Neurol. 1999, 45:200-206.
47. Costello D.J., et al. Concurrent hereditary haemochromatosis and idiopathic Parkinson's disease: a case report series. J. Neurol. Neurosurg. Psychiatry 2004, 75:631-633.
48. Cozzi A., et al. Oxidative stress and cell death in cells expressing l-ferritin variants causing neuroferritinopathy. Neurobiol. Dis. 2010, 37:77-85.
49. Crichton R.R., et al. Brain iron metabolism and its perturbation in neurological diseases. J. Neural Transm. 2011, 118:301-314.
50. Curtis A.R., et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 2001, 28:350-354.
51. Daimon M., et al. A novel mutation of the ceruloplasmin gene in a patient with heteroallelic ceruloplasmin gene mutation (HypoCPGM). Tohoku J. Exp. Med. 2000, 191:119-125.
52. De Grandis E., et al. MR imaging findings in 2 cases of late infantile GM1 gangliosidosis. AJNR Am. J. Neuroradiol. 2009, 30:1325-1327.
53. Delatycki M.B., et al. Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann. Neurol. 1999, 45:673-675.
54. Deng X., et al. Accumulation of oxidative DNA damage in brain mitochondria in mouse model of hereditary ferritinopathy. Neurosci. Lett. 2010, 479:44-48.
55. Devos D., et al. Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation. Brain 2009, 132:e109.
56. Dexter D.T., et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991, 114(Pt. 4):1953-1975.
57. Dick K.J., et al. Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35). Hum. Mutat. 2010, 31:E1251-E1260.
58. Dong X.P., et al. The type IV mucolipidosis-associated protein TRPML1 is an endolysosomal iron release channel. Nature 2008, 455:992-996.
59. Drayer B., et al. MRI of brain iron. AJR Am. J. Roentgenol. 1986, 147:103-110.
60. Drayer B., et al. Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content?. AJR Am. J. Roentgenol. 1987, 149:357-363.
61. Du G., et al. Combined R2*and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov. Disord. 2011, 26:1627-1632.
62. Dwork A.J., et al. An autoradiographic study of the uptake and distribution of iron by the brain of the young rat. Brain Res. 1990, 518:31-39.
63. Edvardson S., et al. Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia. Am. J. Hum. Genet. 2008, 83:643-648.
64. Eiberg H., et al. Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9). Clin. Genet. 2011, doi:10.1111/j.1399-0004.2011.01745.x.
65. Engel L.A., et al. Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism. PLoS One 2010, 5:e12897.
66. Erro R., et al. The "eye of the tiger" sign in pure akinesia with gait freezing. Neurol. Sci. 2011, 32:703-705.
67. Ezquerra M., et al. Association study of the G258S transferrin gene polymorphism and Parkinson's disease in the Spanish population. J. Neurol. 2005, 252:1269-1270.
68. Farrall A.J., Wardlaw J.M. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol. Aging 2009, 30:337-352.
69. Fasano A., et al. Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability. Mov. Disord. 2008, 23:751-755.
70. Faucheux B.A., et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:9603-9607.
71. Faucheux B.A., et al. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 1999, 353:981-982.
72. Faucheux B.A., et al. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 2002, 83:320-330.
73. Faucheux B.A., et al. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 2003, 86:1142-1148.
74. Feder J.N., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 1996, 13:399-408.
75. Feve A.P., et al. Axial motor disturbances after hypoxic lesions of the globus pallidus. Mov. Disord. 1993, 8:321-326.
76. Finkenstedt A., et al. Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. J. Hepatol. 2010, 53:1101-1107.
77. Fishman J.B., et al. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 1987, 18:299-304.
78. Fleming M.D. Congenital sideroblastic anemias: iron and heme lost in mitochondrial translation. Hematology Am. Soc. Hematol. Educ. Program 2011, 2011:525-531.
79. Forni G.L., et al. Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov. Disord. 2008, 23:904-907.
80. Frauscher B., et al. Restless legs syndrome in Friedreich ataxia: a polysomnographic study. Mov. Disord. 2011, 26:302-306.
81. Frei K.P., et al. Mucolipidosis type IV: characteristic MRI findings. Neurology 1998, 51:565-569.
82. Friedman A., et al. Iron as a cause of Parkinson disease - a myth or a well established hypothesis?. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S212-S214.
83. Friedman A., et al. Ferritin as an important player in neurodegeneration. Parkinsonism Relat. Disord. 2011, 17:423-430.
84. Fukunaga M., et al. Layer-specific variation of iron content in cerebral cortex as a source of MRI contrast. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3834-3839.
85. Galluzzi P., et al. MR brain imaging of fucosidosis type I. AJNR Am. J. Neuroradiol. 2001, 22:777-780.
86. Ganz T., Nemeth E. Hepcidin and disorders of iron metabolism. Annual Review of Medicine 2011, Vol. 62:347-360. Annual Reviews, Palo Alto, 2011.
87. Gao X., et al. Restless legs syndrome and Parkinson's disease in men. Mov. Disord. 2010, 25:2654-2657.
88. Garone C., et al. FA2H-related disorders: a novel c.270+3A>T splice-site mutation leads to a complex neurodegenerative phenotype. Dev. Med. Child Neurol. 2011, 53:958-961.
89. Gille G., Reichmann H. Iron-dependent functions of mitochondria-relation to neurodegeneration. J. Neural Transm. 2011, 118:349-359.
90. Gitler A.D., et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet. 2009, 41:308-315.
91. Godau J., et al. Multiregional brain iron deficiency in restless legs syndrome. Mov. Disord. 2008, 23:1184-1187.
92. Goldstein S., et al. The Fenton reagents. Free Radic. Biol. Med. 1993, 15:435-445.
93. Gonzalez-Cuyar L.F., et al. Redox active iron accumulation in aceruloplasminemia. Neuropathology 2008, 28:466-471.
94. Good P.F., et al. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 1992, 593:343-346.
95. Gorell J.M., et al. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995, 45:1138-1143.
96. Gregory A., Hayflick S.J. Genetics of neurodegeneration with brain iron accumulation. Curr. Neurol. Neurosci. Rep. 2011, 11:254-261.
97. Gregory A., et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 2008, 71:1402-1409.
98. Gregory A., et al. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J. Med. Genet. 2009, 46:73-80.
99. Gupta D., et al. Utility of susceptibility-weighted MRI in differentiating Parkinson's disease and atypical parkinsonism. Neuroradiology 2010, 52:1087-1094.
100. Hallgren B., Sourander P. The effect of age on the non-haemin iron in the human brain. J. Neurochem. 1958, 3:41-51.
101. Hama H. Fatty acid 2-hydroxylation in mammalian sphingolipid biology. Biochim. Biophys. Acta 2010, 1801:405-414.
102. Harris Z.L., et al. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:2539-2543.
103. Harris Z.L., et al. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:10812-10817.
104. Hartig M.B., et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann. Neurol. 2006, 59:248-256.
105. Hartig M.B., et al. Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am. J. Hum. Genet. 2011, 89:543-550.
106. Hayflick S.J., et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N. Engl. J. Med. 2003, 348:33-40.
107. Hayflick S.J., et al. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am. J. Neuroradiol. 2006, 27:1230-1233.
108. He Q., et al. DMT1 polymorphism and risk of Parkinson's disease. Neurosci. Lett. 2011, 501:128-131.
109. Hellier K.D., et al. X-linked sideroblastic anaemia with ataxia: another mitochondrial disease?. J. Neurol. Neurosurg. Psychiatry 2001, 70:65-69.
110. Hida A., et al. Aceruloplasminemia in a Japanese woman with a novel mutation of CP gene: clinical presentations and analysis of genetic and molecular pathogenesis. J. Neurol. Sci. 2010, 298:136-139.
111. Hilditch-Maguire P., et al. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum. Mol. Genet. 2000, 9:2789-2797.
112. Hochstrasser H., et al. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 2004, 63:1912-1917.
113. Hou J.G., Jankovic J. Movement disorders in Friedreich's ataxia. J. Neurol. Sci. 2003, 206:59-64.
114. Houlden H., et al. Compound heterozygous PANK2 mutations confirm HARP and Hallervorden-Spatz syndromes are allelic. Neurology 2003, 61:1423-1426.
115. Huang E., et al. Upregulation of iron regulatory proteins and divalent metal transporter-1 isoforms in the rat hippocampus after kainate induced neuronal injury. Exp. Brain Res. 2006, 170:376-386.
116. Ismail E.A., et al. Fucosidosis: immunological studies and chronological neuroradiological changes. Acta Paediatr. 1999, 88:224-227.
117. Jana A., et al. Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death. J. Neurol. Sci. 2009, 278:5-15.
118. Jeong S.Y., David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J. Biol. Chem. 2003, 278:27144-27148.
119. Jeyakumar M., et al. Critical role of iron in the pathogenesis of the murine gangliosidoses. Neurobiol. Dis. 2009, 34:406-416.
120. Jiang H., et al. Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra. Neurochem. Int. 2007, 51:32-36.
121. Jin L., et al. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 2011, 134:50-58.
122. Johansson A.C., et al. Regulation of apoptosis-associated lysosomal membrane permeabilization. Apoptosis 2010, 15:527-540.
123. Johnston M.V., Hoon A.H. Possible mechanisms in infants for selective basal ganglia damage from asphyxia, kernicterus, or mitochondrial encephalopathies. J. Child Neurol. 2000, 15:588-591.
124. Kaneko K., et al. Extensive brain pathology in a patient with aceruloplasminemia with a prolonged duration of illness. Hum. Pathol. 2011, doi:10.1016/j.humpath.2011.05.016.
125. Kastner A., et al. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?. J. Neurochem. 1992, 59:1080-1089.
126. Kaur D., et al. Glutathione depletion in immortalized midbrain-derived dopaminergic neurons results in increases in the labile iron pool: implications for Parkinson's disease. Free Radic. Biol. Med. 2009, 46:593-598.
127. Kauther K.M., et al. The PLA2G6 gene in early-onset Parkinson's disease. Mov. Disord. 2011, 26:2415-2417.
128. Ke Y., Qian Z.M. Brain iron metabolism: neurobiology and neurochemistry. Prog. Neurobiol. 2007, 83:149-173.
129. Kell D.B. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch. Toxicol. 2010, 84:825-889.
130. Khateeb S., et al. PLA2G6 mutation underlies infantile neuroaxonal dystrophy. Am. J. Hum. Genet. 2006, 79:942-948.
131. Klopstock T., et al. Mutations in the pantothenate kinase gene PANK2 are not associated with Parkinson disease. Neurosci. Lett. 2005, 379:195-198.
132. Koeppen A.H., et al. The dentate nucleus in Friedreich's ataxia: the role of iron-responsive proteins. Acta Neuropathol. 2007, 114:163-173.
133. Koeppen A.H., et al. The neuropathology of late-onset Friedreich's ataxia. Cerebellum 2011, 10:96-103.
134. Kono S., Miyajima H. Molecular and pathological basis of aceruloplasminemia. Biol. Res. 2006, 39:15-23.
135. Kono S., et al. Biological effects of mutant ceruloplasmin on hepcidin-mediated internalization of ferroportin. Biochim. Biophys. Acta 2010, 1802:968-975.
136. Kruer M.C., et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann. Neurol. 2010, 68:611-618.
137. Kruer M.C., et al. Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration. Brain 2011, 134:947-958.
138. Kruer M.C., et al. Neuroimaging features of neurodegeneration with brain iron accumulation. AJNR Am. J. Neuroradiol. 2011, doi:10.3174/ajnr.A2677.
139. Kubota A., et al. A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: description of clinical features and implications for genotype-phenotype correlations. Mov. Disord. 2009, 24:441-445.
140. Kuhn J., et al. Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate. Brain Dev. 2007, 29:450-453.
141. Kumar N., et al. The "eye-of-the-tiger" sign is not pathognomonic of the PANK2 mutation. Arch. Neurol. 2006, 63:292-293.
142. Kurian M.A., et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008, 70:1623-1629.
143. Kurian M.A., et al. Childhood disorders of neurodegeneration with brain iron accumulation (NBIA). Dev. Med. Child Neurol. 2011, 53:394-404.
144. Kurisaki H., et al. Multiple system atrophy with a-/hypo-ceruloplasminemia: distribution of iron in brains of 2 autopsy cases. Rinsho Shinkeigaku 2002, 42:293-298.
145. Kurz T., et al. The role of lysosomes in iron metabolism and recycling. Int. J. Biochem. Cell Biol. 2011, 43:1686-1697.
146. Kwiatkowski A., et al. Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation. Parkinsonism Relat. Disord. 2012, 18:110-112.
147. Lee D.W., et al. Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J. Biol. Chem. 2009, 284:29065-29076.
148. Lees A.J., Singleton A.B. Clinical heterogeneity of ATP13A2 linked disease (Kufor-Rakeb) justifies a PARK designation. Neurology 2007, 68:1553-1554.
149. Lei X., et al. Group VIA Ca2+-independent phospholipase A2 (iPLA2beta) and its role in beta-cell programmed cell death. Biochimie 2010, 92:627-637.
150. Levi S., Rovida E. The role of iron in mitochondrial function. Biochim. Biophys. Acta 2009, 1790:629-636.
151. Li X., et al. Iron chelation and neuroprotection in neurodegenerative diseases. J. Neural Transm. 2011, 118:473-477.
152. Lim B.C., et al. Pantothenate kinase-associated neurodegeneration in Korea: recurrent R440P mutation in PANK2 and outcome of deep brain stimulation. Eur. J. Neurol. 2011, doi:10.1111/j.1468-1331.2011.03589.x.
153. Lirong J., et al. Hypoceruloplasminemia-related movement disorder without Kayser-Fleischer rings is different from Wilson disease and not involved in ATP7B mutation. Eur. J. Neurol. 2009, 16:1130-1137.
154. Lobmayr L., et al. Increased IRP1 activity in Friedreich ataxia. Gene 2005, 354:157-161.
155. Loreal O., et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J. Hepatol. 2002, 36:851-856.
156. Maciel P., et al. Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement. Neurology 2005, 65:603-605.
157. Mahoney R., et al. Cognitive functioning in children with pantothenate-kinase-associated neurodegeneration undergoing deep brain stimulation. Dev. Med. Child Neurol. 2011, 53:275-279.
158. Malik I., et al. Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. Am. J. Pathol. 2008, 172:406-416.
159. Mancuso M., et al. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J. Neuropathol. Exp. Neurol. 2005, 64:280-294.
160. Mariani R., et al. Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation. Gut 2004, 53:756-758.
161. Marmolino D. Friedreich's ataxia: past, present and future. Brain Res. Rev. 2011, 67:311-330.
162. Mastroberardino P.G., et al. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol. Dis. 2009, 34:417-431.
163. Matsunaga T., et al. Ceramide-induced intracellular oxidant formation, iron signaling, and apoptosis in endothelial cells: protective role of endogenous nitric oxide. J. Biol. Chem. 2004, 279:28614-28624.
164. McNeill A., Chinnery P.F. Neurodegeneration with brain iron accumulation. Handb. Clin. Neurol. 2011, 100:161-172.
165. McNeill A., et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008, 70:1614-1619.
166. McNeill A., et al. The neurological presentation of ceruloplasmin gene mutations. Eur. Neurol. 2008, 60:200-205.
167. Michael S., et al. Iron and iron-responsive proteins in the cardiomyopathy of Friedreich's ataxia. Cerebellum 2006, 5:257-267.
168. Mir P., et al. Adult-onset generalized dystonia due to a mutation in the neuroferritinopathy gene. Mov. Disord. 2005, 20:243-245.
169. Miyajima H. Aceruloplasminemia, an iron metabolic disorder. Neuropathology 2003, 23:345-350.
170. Miyajima H., et al. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987, 37:761-767.
171. Miyajima H., et al. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann. Neurol. 1997, 41:404-407.
172. Miyajima H., et al. Estimation of the gene frequency of aceruloplasminemia in Japan. Neurology 1999, 53:617-619.
173. Miyajima H., et al. Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation. Neurology 2001, 57:2205-2210.
174. Miyajima H., et al. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals 2003, 16:205-213.
175. Morgan N.V., et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat. Genet. 2006, 38:752-754.
176. Morris C.M., et al. Histochemical distribution of non-haem iron in the human brain. Acta Anat. (Basel) 1992, 144:235-257.
177. Naidoo N., et al. Human genetics and genomics a decade after the release of the draft sequence of the human genome. Hum. Genomics 2011, 5:577-622.
178. Najim al-Din A., et al. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol. Scand. 1994, 89:347-352.
179. Nandar W., Connor J.R. HFE gene variants affect iron in the brain. J. Nutr. 2011, 141:729S-739S.
180. Nguyen T., et al. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11840-11845.
181. Nielsen J.E., et al. Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J. Neurol. Neurosurg. Psychiatry 1995, 59:318-321.
182. Ogimoto M., et al. Criteria for early identification of aceruloplasminemia. Intern. Med. 2011, 50:1415-1418.
183. Ohta E., et al. Neuroferritinopathy in a Japanese family with a duplication in the ferritin light chain gene. Neurology 2008, 70:1493-1494.
184. Oide T., et al. Iron overload and antioxidative role of perivascular astrocytes in aceruloplasminemia. Neuropathol. Appl. Neurobiol. 2006, 32:170-176.
185. Ondo W.G. Intravenous iron dextran for severe refractory restless legs syndrome. Sleep Med. 2010, 11:494-496.
186. Ondo W.G., et al. Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States. Mov. Disord. 2010, 25:2470-2472.
187. Oner A.Y., et al. Fucosidosis: MRI and MRS findings. Pediatr. Radiol. 2007, 37:1050-1052.
188. Ory-Magne F., et al. Clinical phenotype and neuroimaging findings in a French family with hereditary ferritinopathy (FTL498-499InsTC). Mov. Disord. 2009, 24:1676-1683.
189. Pagani E., et al. Assessment of brain white matter fiber bundle atrophy in patients with Friedreich ataxia. Radiology 2010, 255:882-889.
190. Paisan-Ruiz C., et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann. Neurol. 2009, 65:19-23.
191. Paisan-Ruiz C., et al. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol. Aging 2010, doi:10.1016/j.neurobiolaging.2010.05.009.
192. Pan P.L., et al. Desferrioxamine treatment of aceruloplasminemia: long-term follow-up. Mov. Disord. 2011, 26:2142-2144.
193. Papp M.I., et al. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J. Neurol. Sci. 1989, 94:79-100.
194. Park J.S., et al. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Hum. Mutat. 2011, 32:956-964.
195. Pellecchia M.T., et al. The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology 2005, 64:1810-1812.
196. Peran P., et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010, 133:3423-3433.
197. Perry T.L., et al. Hallervorden-Spatz disease: cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus. Ann. Neurol. 1985, 18:482-489.
198. Poli M., et al. Pantothenate kinase-2 (Pank2) silencing causes cell growth reduction, cell-specific ferroportin upregulation and iron deregulation. Neurobiol. Dis. 2010, 39:204-210.
199. Popescu B.F., et al. The chemical form of mitochondrial iron in Friedreich's ataxia. J. Inorg. Biochem. 2007, 101:957-966.
200. Posse de Chaves E., Sipione S. Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. FEBS Lett. 2010, 584:1748-1759.
201. Potter K.A., et al. Central nervous system dysfunction in a mouse model of FA2H deficiency. Glia 2011, 59:1009-1021.
202. Provenzale J.M., et al. Neuroradiologic findings in fucosidosis, a rare lysosomal storage disease. AJNR Am. J. Neuroradiol. 1995, 16:809-813.
203. Puccio H., et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 2001, 27:181-186.
204. Qian Z.M., et al. Divalent metal transporter 1 is a hypoxia-inducible gene. J. Cell. Physiol. 2011, 226:1596-1603.
205. Rakovic A., et al. Genetic association study of the P-type ATPase ATP13A2 in late-onset Parkinson's disease. Mov. Disord. 2009, 24:429-433.
206. Ramirez A., et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 2006, 38:1184-1191.
207. Rhodes S.L., Ritz B. Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiol. Dis. 2008, 32:183-195.
208. Riederer P., et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 1989, 52:515-520.
209. Ristow M., et al. Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12239-12243.
210. Rossi D., et al. Early-onset neurodegeneration with brain iron accumulation due to PANK2 mutation. Brain Dev. 2011, doi:10.1016/j.braindev.2011.09.010.
211. Russo N., et al. Hereditary haemochromatosis is unlikely to cause movement disorders-a critical review. J. Neurol. 2004, 251:849-852.
212. Salazar J., et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18578-18583.
213. Santoro L., et al. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics 2011, 12:33-39.
214. Sastry S., Arendash G.W. Time-dependent changes in iron levels and associated neuronal loss within the substantia nigra following lesions within the neostriatum/globus pallidus complex. Neuroscience 1995, 67:649-666.
215. Schenck J.F., Zimmerman E.A. High-field magnetic resonance imaging of brain iron: birth of a biomarker?. NMR Biomed. 2004, 17:433-445.
216. Schipper H.M. Neurodegeneration with brain iron accumulation - clinical syndromes and neuroimaging. Biochim. Biophys. Acta. 2011, doi:10.1016/j.bbadis.2011.06.016.
217. Schneider S.A., Bhatia K.P. Dystonia in the Woodhouse Sakati syndrome: a new family and literature review. Mov. Disord. 2008, 23:592-596.
218. Schneider S.A., Bhatia K.P. Three faces of the same gene: FA2H links neurodegeneration with brain iron accumulation, leukodystrophies, and hereditary spastic paraplegias. Ann. Neurol. 2010, 68:575-577.
219. Schneider S.A., et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov. Disord. 2010, 25:979-984.
220. Schneider S.A., et al. Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Mov. Disord. 2011, 27:42-53.
221. Schols L., et al. Friedreich's ataxia. Revision of the phenotype according to molecular genetics. Brain 1997, 120(Pt. 12):2131-2140.
222. Schonberg D.L., McTigue D.M. Iron is essential for oligodendrocyte genesis following intraspinal macrophage activation. Exp. Neurol. 2009, 218:64-74.
223. Schonfeld E., et al. Docosahexaenoic acid enhances iron uptake by modulating iron transporters and accelerates apoptotic death in PC12 cells. Neurochem. Res. 2007, 32:1673-1684.
224. Schwarz J., et al. Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 1996, 60:98-101.
225. Serata D., et al. Hemochromatosis-induced bipolar disorder: a case report. Gen. Hosp. Psychiatry 2012, 34:101e1-101e3.
226. Shachar T., et al. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov. Disord. 2011, 26:1593-1604.
227. Shimada Y., et al. Cloning and chromosomal mapping of a novel ABC transporter gene (hABC7), a candidate for X-linked sideroblastic anemia with spinocerebellar ataxia. J. Hum. Genet. 1998, 43:115-122.
228. Sian-Hulsmann J., et al. The relevance of iron in the pathogenesis of Parkinson's disease. J. Neurochem. 2011, 118:939-957.
229. Simmons D.A., et al. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 2007, 55:1074-1084.
230. Snyder A.M., et al. Mitochondrial ferritin in the substantia nigra in restless legs syndrome. J. Neuropathol. Exp. Neurol. 2009, 68:1193-1199.
231. Steenweg M.E., et al. Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain 2010, 133:2971-2982.
232. Strecker K., et al. Eye of the tiger sign in multiple system atrophy. Eur. J. Neurol. 2007, 14:e1-e2.
233. Synofzik M., et al. Restless legs and substantia nigra hypoechogenicity are common features in Friedreich's ataxia. Cerebellum 2011, 10:9-13.
234. Tan E.K., et al. PLA2G6 mutations and Parkinson's disease. Ann. Neurol. 2010, 67:148.
235. Tan J., et al. Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein. J. Biol. Chem. 2011, 286:29654-29662.
236. Taylor E.M., Morgan E.H. Developmental changes in transferrin and iron uptake by the brain in the rat. Brain Res. Dev. Brain Res. 1990, 55:35-42.
237. Taylor E.M., Morgan E.H. Role of transferrin in iron uptake by the brain: a comparative study. J. Comp. Physiol. B 1991, 161:521-524.
238. Thomas M., et al. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov. Disord. 2004, 19:36-42.
239. Timmermann L., et al. Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation. Brain 2010, 133:701-712.
240. Todorich B., et al. Oligodendrocytes and myelination: the role of iron. Glia 2009, 57:467-478.
241. Tomiyama H., et al. PLA2G6 variant in Parkinson's disease. J. Hum. Genet. 2011, 56:401-403.
242. Tribl F., et al. Subcellular proteomics reveals neuromelanin granules to be a lysosome-related organelle. J. Neural Transm. 2006, 113:741-749.
243. Tribl F., et al. Identification of l-ferritin in neuromelanin granules of the human substantia nigra: a targeted proteomics approach. Mol. Cell. Proteomics 2009, 8:1832-1838.
244. Uversky V.N., et al. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 2001, 276:44284-44296.
245. Van Craenenbroeck A., et al. Hallervorden-Spatz disease: historical case presentation in the spotlight of nosological evolution. Mov. Disord. 2010, 25:2486-2492.
246. van der Hoorn A., et al. Handedness correlates with the dominant parkinson side: a systematic review and meta-analysis. Mov. Disord. 2011, n/a-n/a.
247. Van Eden M.E., Aust S.D. Intact human ceruloplasmin is required for the incorporation of iron into human ferritin. Arch. Biochem. Biophys. 2000, 381:119-126.
248. Velasco-Sanchez D., et al. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 2011, 10:1-8.
249. Vidal R., et al. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J. Neuropathol. Exp. Neurol. 2004, 63:363-380.
250. Vinod Desai S., et al. Relaxation and susceptibility MRI characteristics in Hallervorden-Spatz syndrome. J. Magn. Reson. Imaging 2007, 25:715-720.
251. Vymazal J., et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 1999, 211:489-495.
252. Vymazal J., et al. MR relaxometry in Huntington's disease: correlation between imaging, genetic and clinical parameters. J. Neurol. Sci. 2007, 263:20-25.
253. Wada H., et al. Establishment of an improved mouse model for infantile neuroaxonal dystrophy that shows early disease onset and bears a point mutation in Pla2g6. Am. J. Pathol. 2009, 175:2257-2263.
254. Wakabayashi K., et al. Mucolipidosis type IV: an update. Mol. Genet. Metab. 2011, 104:206-213.
255. Waldvogel D., et al. Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann. Neurol. 1999, 46:123-125.
256. Wallis L.I., et al. MRI assessment of basal ganglia iron deposition in Parkinson's disease. J. Magn. Reson. Imaging 2008, 28:1061-1067.
257. Walshe J.M. Diagnostic significance of reduced serum caeruloplasmin concentration in neurological disease. Mov. Disord. 2005, 20:1658-1661.
258. Wang J., et al. Ferroportin1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats. Eur. J. Neurosci. 2007, 25:2766-2772.
259. Wang Y., et al. Different iron-deposition patterns of multiple system atrophy with predominant Parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am. J. Neuroradiol. 2011, doi:10.3174/ajnr.A2765.
260. Wenning G.K., et al. Multiple system atrophy: a primary oligodendrogliopathy. Ann. Neurol. 2008, 64:239-246.
261. Wesemann W., et al. Intranigral injected iron progressively reduces striatal dopamine metabolism. J. Neural. Transm. Park. Dis. Dement. Sect. 1994, 8:209-214.
262. Willems P.J., et al. Fucosidosis revisited: a review of 77 patients. Am. J. Med. Genet. 1991, 38:111-131.
263. Williams R., et al. Pathogenic implications of iron accumulation in multiple sclerosis. J. Neurochem. 2012, 120:7-25.
264. Wolkow N., et al. Aceruloplasminemia: retinal histopathologic manifestations and iron-mediated melanosome degradation. Arch. Ophthalmol. 2011, 129:1466-1474.
265. Woodhouse N.J., Sakati N.A. A syndrome of hypogonadism, alopecia, diabetes mellitus, mental retardation, deafness, and ECG abnormalities. J. Med. Genet. 1983, 20:216-219.
266. Wu Y., et al. Clinical study and PLA2G6 mutation screening analysis in Chinese patients with infantile neuroaxonal dystrophy. Eur. J. Neurol. 2009, 16:240-245.
267. Wu Y., et al. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem. Int. 2010, 57:198-205.
268. Xu X., et al. Age, gender, and hemispheric differences in iron deposition in the human brain: an in vivo MRI study. Neuroimage 2008, 40:35-42.
269. Yao B., et al. Susceptibility contrast in high field MRI of human brain as a function of tissue iron content. Neuroimage 2009, 44:1259-1266.
270. Yoshino H., et al. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 2010, 75:1356-1361.
271. Zecca L., et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 2001, 76:1766-1773.
272. Zecca L., et al. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol. 2008, 116:47-55.
273. Zhang Y., et al. Lysosomal proteolysis is the primary degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for iron exit. Antioxid. Redox Signal. 2010, 13:999-1009.
274. Zhao Z., et al. Genetic ablation of PLA2G6 in mice leads to cerebellar atrophy characterized by Purkinje cell loss and glial cell activation. PLoS One 2011, 6:e26991.
275. Zheng W., Monnot A.D. Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases. Pharmacol. Ther. 2011, doi:10.1016/j.pharmthera.2011.10.006.
276. Zhou B., et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat. Genet. 2001, 28:345-349.
277. Zoller I., et al. Absence of 2-hydroxylated sphingolipids is compatible with normal neural development but causes late-onset axon and myelin sheath degeneration. J. Neurosci. 2008, 28:9741-9754.
278. Zorzi G., et al. Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov. Disord. 2011, 26:1756-1759.